GlassScriptPhysician profile
Jeffrey M Cohen
NPI 1942275383
$4,948.75
in general payments reported to CMS, 2019-2025
34 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $196 · 2021: $596 · 2022: $951 · 2023: $1,064 · 2024: $717 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.56 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $791.70 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $390.25 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $385.67 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $379.49 | 2022-2025 | Jynarque |
| Glaxosmithkline, LLC. | $328.31 | 2020-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $301.40 | 2022-2024 | Purified Cortrophin Gel |
| Amgen INC. | $286.86 | 2020-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $249.05 | 2023-2025 | |
| Baxter Healthcare | $225.48 | 2019-2024 | Renal - Pd |
| Mallinckrodt Hospital Products INC. | $182.53 | 2020-2025 | Terlivaz |
| Akebia Therapeutics INC | $169.96 | 2021-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $167.15 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $121.40 | 2020-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $108.38 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $97.17 | 2019-2025 | Velphoro, Korsuva, Velphoro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $89.09 | 2025 | Renal - Pd |
| Mallinckrodt Enterprises LLC | $81.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.15 | 2019-2023 | Gattex |
| Novo Nordisk INC | $63.82 | 2021-2023 | Ozempic |
| Travere Therapeutics, INC. | $61.55 | 2023-2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $55.82 | 2025 | Voyxact |
| Renalytix Ai, INC. | $47.22 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.11 | 2024-2025 | Jardiance |
| Kyowa Kirin, INC. | $35.26 | 2024-2025 | Crysvita |
| Genentech USA, INC. | $30.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.80 | 2019 | |
| Scpharmaceuticals INC. | $25.44 | 2025 | |
| Nuwellis, INC. | $23.57 | 2022 | |
| Ardelyx, INC. | $22.73 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.11 | 2019 | |
| Cycle Pharmaceuticals INC | $18.66 | 2025 | Venxxiva |
| Alnylam Pharmaceuticals INC. | $16.62 | 2024 | Givlaari |
| Lilly USA, LLC | $16.58 | 2025 | Jardiance |
| Ethicon US, LLC | $16.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.